Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

A Study To Evaluate The Safety Of Voriconazole As Treatment Of Invasive Aspergillosis (Fungal Infection) And Other Rare Molds In Children

This study has been terminated.
(This protocol terminated prematurely on July 8, 2013 due to slow enrollment, not because of any safety issues or concerns.)
Information provided by (Responsible Party):
Pfizer Identifier:
First received: February 3, 2009
Last updated: August 16, 2016
Last verified: August 2016
The purpose of this study is to evaluate the safety profile of voriconazole (an antifungal drug) when used in children who have invasive aspergillosis (IA) and other rare systemic fungal infections.

Condition Intervention Phase
Invasive Aspergillosis
Drug: Voriconazole
Phase 3

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Prospective, Open-label, Non-randomized, Multi-center Study To Investigate The Safety And Tolerability Of Voriconazole As Primary Therapy For Treatment Of Invasive Aspergillosis And Molds Such As Scedosporium Or Fusarium Species In Pediatric Patients.

Resource links provided by NLM:

Further study details as provided by Pfizer:

Primary Outcome Measures:
  • Number of Participants With Adverse Events (AEs) [ Time Frame: Baseline, daily while hospitalized, Days 7, 14, 28, 42, 84, and 114, at end of treatment, and up to 1 month post treatment ]

Secondary Outcome Measures:
  • Percentage of Participants With a Global Response of Success [ Time Frame: Weeks 6 and End of Treatment (EOT; up to Week 12) ]
    Percentage of participants with global response of success at Weeks 6 and at EOT (up to Week 12). Global response of success was defined as a participant who achieved a complete or partial global response per the investigator. Complete response was defined as resolution of all clinical signs and symptoms PLUS resolution of 90 percent (%) or more of the lesions visible on radiological studies and attributed to invasive aspergillosis (IA) at Baseline. Partial response was defined as clinical improvement PLUS 50% to <90% resolution of the radiological lesions attributed to IA at Baseline.

  • All-Cause Mortality - Number of Participant Deaths [ Time Frame: Week 6 and EOT (up to Week 12) ]
    Number of participant deaths reported at Week 6 and at EOT (up to Week 12).

  • Attributable Mortality - Number of Participant Deaths [ Time Frame: Weeks 6 and EOT (up to Week 12) ]
    Number of participant deaths attributable to study drug reported at Week 6 and at EOT (up to Week 12).

  • Time to Death [ Time Frame: Baseline up to 1 month post treatment ]

Enrollment: 31
Study Start Date: May 2009
Study Completion Date: May 2013
Primary Completion Date: May 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Children from 2 to 17 years who have possible, probable or proven invasive aspergillosis, or other rare mold infection (eg, Scedosporium and Fusarium).
Drug: Voriconazole

All subjects will receive voriconazole for a minimum of 6 weeks and a maximum of 12 weeks. All subjects must receive intravenous (IV) voriconazole for the first week of therapy.

Group 1: Subjects 2 to 11 years old and subjects 12 to 14 years old with low body weight (<50 kg) will receive 9 mg/kg IV every 12 hours (q12h) on day 1, then 8 mg/kg IV q12h starting day 2. If there is a significant clinical improvement after the first week of IV therapy, subjects may be switched to the step-down oral regimen (9 mg/kg PO q12h with a maximum dose of 350 mg PO q12h) at the discretion of the investigator.

Group 2: Subjects 12 to 17 years old (excluding 12-14-year-olds weighing <50 kg) will receive 6 mg/kg IV q12h on day 1, then 4 mg/kg IV q12h starting day 2. Similar to Group 1, subjects may be switched to the step-down oral regimen (200 mg PO q12h) at the discretion of the investigator. Oral voriconazole can be administered as tablet or oral suspension.


Ages Eligible for Study:   2 Years to 17 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Immunocompromised with clinically compatible illness.
  • Diagnosis of proven or probable or possible Invasive Aspergillosis (based on a modified version of the revised EORTC/MSG consensus definitions).
  • Diagnosis of infection due to Scedosporium or Fusarium species.
  • Male and female from 2 to 17 years of age.
  • Females with childbearing potential must have negative pregnancy test and be using appropriate contraception.

Exclusion Criteria:

  • Allergy or hypersensitivity to the azole drugs.
  • Female subjects who are pregnant or lactating.
  • Patients who received more than four days of antifungal drugs to treat the current episode of invasive aspergillosis or rare mold infection.
  • Received within 24 hours prior to enrollment drugs that may cause QT interval prolongation.
  • Significant liver, kidney or heart dysfunction.
  • Not expected to survive for at least 5 days.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00836875

United States, California
Childrens Hospital Los Angeles
Los Angeles, California, United States, 90027
Children's Hospital & Research Center Oakland (CHRCO)
Oakland, California, United States, 94609
United States, Pennsylvania
Children's Hospital of Pittsburgh of UPMC
Pittsburgh, Pennsylvania, United States, 15224
United States, Texas
The University of Texas MD Anderson Cancer Center
Houston, Texas, United States, 77030
United States, Virginia
Children's Pavilion, Virginia Commonwealth University Health System
Richmond, Virginia, United States, 23219
Virginia Commonwealth University Health System, Hospital Pharmacy
Richmond, Virginia, United States, 23298-0042
Pediatric Hematology and Oncology, Virginia Commonwealth University Health System
Richmond, Virginia, United States, 23298
Virginia Commonwealth University/MCV Clinical Pathology
Richmond, Virginia, United States, 23298
Virginia Commonwealth University
Richmond, Virginia, United States, 23298
Canada, Alberta
Alberta Children's Hospital, Pediatric Oncology Office
Calgary, Alberta, Canada, T3B 6A8
Alberta Children's Hospital
Calgary, Alberta, Canada, T3B 6A8
Czech Republic
Fakultni nemocnice Brno
Brno, Czech Republic, 625 00
Fakultni nemocnice Brno
Brno, Czech Republic, 62500
UMC St. Radboud
Nijmegen, Netherlands, 6500 HB
Klinika Transplantacji Szpiku, Onkologii i Hematologii Dzieciecej
Wroclaw, Poland, 50-345
National University Hospital
Singapore, Singapore, 119074
KK Women's and Children's Hospital
Singapore, Singapore, 229899
Hospital General Universitari Vall D'Hebron
Barcelona, Spain, 08035
Hospital Universitari Vall d'Hebron. Servicio de Farmacia
Barcelona, Spain, 08035
Hospital Universitario Vall d'Hebron
Barcelona, Spain, 08035
Madrid, Spain, 28041
Hospital Universitario 12 de Octubre
Madrid, Spain, 28041
Department of Pediatrics, Faculty of Medicine, Siriraj Hospital, Mahidol University
Bangkok noi, Bangkok, Thailand, 10700
Department of Pediatrics, Faculty of Medicine, Chulalongkorn University
Patumwan, Bangkok, Thailand, 10330
Department of Pediatrics, Phramongkutklao hospital
Rajathevee, Bangkok, Thailand, 10400
Sponsors and Collaborators
Study Director: Pfizer Call Center Pfizer
  More Information

Additional Information:
Responsible Party: Pfizer Identifier: NCT00836875     History of Changes
Other Study ID Numbers: A1501080
2008-005275-10 ( EudraCT Number )
Study First Received: February 3, 2009
Results First Received: May 9, 2014
Last Updated: August 16, 2016

Keywords provided by Pfizer:
Pediatrics voriconazole invasive fungal infection invasive aspergillosis immunocompromized

Additional relevant MeSH terms:
Skin Diseases, Infectious
Skin Diseases
Antifungal Agents
Anti-Infective Agents
14-alpha Demethylase Inhibitors
Cytochrome P-450 Enzyme Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Steroid Synthesis Inhibitors
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Cytochrome P-450 CYP3A Inhibitors processed this record on May 25, 2017